Pink sheet retail investor AIDS-turned-Cancer-turned-Coronacrap favorite Cytodyn (CYDY) has been quite the darling of the stuck-at-home newbie trader crowd lately. It seems not a day goes by without some form of stock promotion. And today, 28 April, is no exception.
Presenting an absolute howler of a puff piece on Seeking Alpha, entitled “Finding The Kink In COVID-19’s Armor – Preventing ARDS” by one Theodore Zucconi.
Here’s his bio on Seeking Alpha:
Ted’s piece this morning hypes up not just Cytodyn (CYDY), but also Galectin (GALT), and Ampio (AMPE) of all things. He’s written a few other times hyping CYDY as well. Remember the 13 shots on goal laugher? “CytoDyn’s 13 Shots On Goal De-Risk Investment”
Here is his disclosure statement on today’s article:
Ignore the fact that he is long, focus on the last sentence, and keep it in mind, dear reader, as you continue.
Some may recall that Galectin was once called Pro Pharmaceuticals (PRW then PRWP).
And those with really good memories, might recall that Theodore Zucconi was the CEO and a director (until 2018!):
Seems like that disclosure is a little light?
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.